Image For Activity Cover
The Lead Episode 43: A Discussion of Implantable Subcutaneous Cardioverter-Defibrillators in Patients with Congenital Heart Disease
Description
Peter Aziz from Cleveland Clinic Foundation is joined by guests Maully J Shah, MBBS, FACC, FHRS, CCDS, CEPS, Director of pediatric EP at CHOP, and Professor of Pediatrics at the Perelman School of Medicine at University of Pennsylvania; Johannes von Alvensleben, MD., Director of Adult Congenital Arrhythmia Services at Children’s Hospital Colorado to discuss Implantable Subcutaneous Cardioverter-Defibrillators in Patients with Congenital Heart Disease.
Learning Objectives
  • Examine the efficacy, burden of complications, and rates of appropriate vs inappropriate therapy using the S-ICD in ACHD.
Article Authors and Podcast Contributors
Article Authors
Nicolas Combes, Pascal Defaye, Jean-Claude Deharo, Philippe Durand, Guillaume Duthoit, Romain Eschalier, Laurent Fauchier, Rodrigue Garcia, Olivier Geoffroy, Edouard Gitenay, Jean-Baptiste Gourraud, Charles Guenancia, Laurence Iserin, Peggy Jacon, Laurence Jesel-Morel, Fawzi Kerkouri, Didier Klug, Linda Koutbi, Fabien Labombarda, Magalie Ladouceur, Gabriel Laurent, Christophe Leclercq, Baptiste Maille, Alice Maltret, Grégoire Massoulié, Pierre Mondoly, Sandro Ninni, Pierre Ollitrault, Jean-Luc Pasquié, Bertrand Pierre, Pénélope Pujadas, Laure Champ-Rigot, Frédéric Sacher, Nicolas Sadoul, Alexandre Schatz, Pierre Winum, Paul-Ursmar Milliez, Vincent Probst, Eloi Marijon 

Podcast Contributors
Peter F. Aziz, MD, FHRS, of Cleveland Clinic Foundation

Maully J Shah, MBBS, FACC, FHRS, CCDS, CEPS, Director of pediatric EP at CHOP and Professor of Pediatrics at the Perelman School of Medicine at University of Pennsylvania 
Johannes von Alvensleben, MD, Director of Adult Congenital Arrhythmia Services at Children’s Hospital Colorado 
Disclosure Policy

ACE Disclosure Policy

The Heart Rhythm Society is committed to the provision of Accredited Continuing Education (formerly known as Continuing Medical Education (CME)) that is balanced, objective, and evidence based. HRS adheres to the Standards for Integrity and Independence in Accredited Continuing Education of the Accreditation Council for Continuing Medical Education (ACCME) which require that those individuals in a position to control the content of an educational activity (including, but not limited to, planners, faculty, authors, committee members, content reviewers, editors, and staff) disclose all financial relationships with an ACCME-defined ineligible company* within the 24 months prior to the disclosure.

 

Any individual who refuses to disclose financial relationships is disqualified from participating in HRS ACE-certified activities. Owners and employees of ACCME-defined ineligible companies may have no role in the planning or implementation of ACE activities without a special written exemption from the HRS Chief Learning Officer that will be granted only in specific circumstances that meet ACCME requirements.


ACCME Definition:

*An ineligible company is one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Examples of such organizations include:

  • Advertising, marketing, or communication firms whose clients are ineligible companies
  • Bio-medical startups that have begun a governmental regulatory approval process
  • Compounding pharmacies that manufacture proprietary compounds
  • Device manufacturers or distributors
  • Diagnostic labs that sell proprietary products
  • Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
  • Manufacturers of health-related wearable products
  • Pharmaceutical companies or distributors
  • Pharmacy benefit managers
  • Reagent manufacturers or sellers

 

All relevant financial relationships have been mitigated.

Host Disclosure(s):
P. Aziz: No relevant financial relationships with ineligible companies to disclose.

Contributor Disclosure(s):
M. Shah:
Board Membership: Journal of the American College of Cardiology, Research: Medtronic, Inc., Honoraria/Speaking and Teaching: Medtronic, Inc, Tenaya Therapeutics
J. Alvensleben: No relevant financial relationships with ineligible companies to disclose. 


Staff Disclosure(s) (note: HRS staff are NOT in control of educational content. Disclosures are provided solely for full transparency to the learner):
J. Glenn: No relevant financial relationships with ineligible companies to disclose. 
S. Sailor: No relevant financial relationships with ineligible companies to disclose.
S. Colbert: No relevant financial relationships with ineligible companies to disclose.
Summary
Availability: On-Demand
Cost: FREE
Credit Offered:
No Credit Offered
Recommended
  Heart Rhythm Society
1325 G Street NW, Suite 500
Washington, DC 20005
P: 202-464-3400 F: 202-464-3401
E: questions@heartrhythm365.org
© Heart Rhythm Society
Privacy Policy | Linking Policy | Patient Education Disclaimer | State Nonprofit Disclosures | FAQ
 
Android App Download IOS App Download Powered By